STOCKHOLM, Sweden, June 22, 2010 /PRNewswire-FirstCall/ -- Diamyd Medical AB has signed an agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), a Johnson & Johnson company, to develop and commercialize the Diamyd(R) diabetes therapy. (Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 ) The agreement relates to the development and world-wide commercialization of the GAD65 antigen-based therapy (Diamyd(R)) for the treatment and prevention of type 1 diabetes and associated conditions. OMJPI will make an upfront payment of USD 45 million, and under the terms of the agreement, Diamyd has the potential to receive additional development and sales milestone payments of up to USD 580 million, as well as tiered royalties on future sales.

STOCKHOLM, October 1 /PRNewswire-FirstCall/ -- Diamyd Medical announces today that the company has signed an agreement with Inclinix Inc., North Carolina, for accelerated recruitment of children and adolescents recently diagnosed with type 1 diabetes in the US Phase III study of the diabetes vaccine Diamyd(R). (Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 ) Diamyd Medical is conducting a global Phase III program with the diabetes vaccine Diamyd(R), including in total 640 children and adolescents with recent-onset type 1 diabetes.

STOCKHOLM, June 8 /PRNewswire-FirstCall/ -- Diamyd Medical reported today that the company has received approval from the US Food and Drug Administration (FDA) to include children with type 1 diabetes from 10 years of age in the company's Phase III study with the diabetes vaccine Diamyd(R). (Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 ) Diamyd Medical is conducting two parallel phase III studies, one in Europe and one in the USA, comprising a total of 640 patients.

STOCKHOLM, March 4 /PRNewswire-FirstCall/ -- Diamyd Medical announces today that the Swedish Medical Products Agency has approved a study with the Diamyd(R) diabetes vaccine in children with high risk to develop type 1 diabetes. (Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 ) "To vaccinate children against diabetes has from the outset been one of Diamyd Medical's long term goals," says Elisabeth Lindner, President and CEO of Diamyd Medical.

Sweden-based biopharmaceutical company Diamyd Medical has reported that six European countries have approved the initiation of a Phase III study with the Diamyd diabetes vaccine for type 1 diabetes.